CollPlant Biotechnologies Ltd (CLGN) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of CollPlant Biotechnologies Ltd stock $2.78, price $3.65, that is 23.8% below the price, quality 52 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
CollPlant Biotechnologies Ltd
CLGN · USExpensive (fair value 24% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $2.73 – $224.80 · fair‑value band $2.09 – $3.48 · the $3.65 price screens above the $2.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether CollPlant Biotechnologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
Show moreShow less
Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds.
It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product.
The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019.
CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Stock analysis
CollPlant Biotechnologies Ltd (CLGN) currently trades at $3.65, while our estimate is $2.78, 24% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $2.09 (bear) to $3.48 (bull), the price of $3.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
CollPlant Biotechnologies Ltd reported revenue of $2.4M in FY2025 versus $15.6M in FY2021, a compound −37.6%/yr. Reported net income was −$11.5M in FY2025.
Key figures
Market cap $11.2M Micro · P/S ratio 38.4 · EPS (TTM) $−9.33 · Return on equity −162% · Return on assets (EBIT) −53.2% (5-year average) · Operating margin −2,438% · Revenue growth (YoY) −39.7% · Free cash flow −$9.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 84% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −24%, CLGN screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 18, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare CollPlant Biotechnologies Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs CLGN |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs CLGN |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,502,600 KRW | +9% | vs CLGN |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs CLGN |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs CLGN |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs CLGN |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs CLGN |
| Revolution Medicines, Inc RVMD | $159.82 | $83.12 | −48% | vs CLGN |
| Celltrion, Inc 068270 | 215,000 KRW | 74,945 KRW | −65% | vs CLGN |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs CLGN |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CollPlant Biotechnologies Ltd (CLGN) overvalued or undervalued?
What is the fair value of CLGN?
What is the quality score of CLGN?
What is the price target for CollPlant Biotechnologies Ltd (CLGN)?
What is the CollPlant Biotechnologies Ltd stock forecast for 2026?
What is the intrinsic value of CollPlant Biotechnologies Ltd (CLGN)?
Is CollPlant Biotechnologies Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of CLGN?
How much is CollPlant Biotechnologies Ltd worth?
What do the bullish and bearish scenarios say about CLGN?
How solid is the balance sheet of CollPlant Biotechnologies Ltd (CLGN)?
How far is CLGN from its 52-week high?
Which stocks are comparable to CollPlant Biotechnologies Ltd?
Is CollPlant Biotechnologies Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of CollPlant Biotechnologies Ltd (CLGN)?
What should I pay attention to with CollPlant Biotechnologies Ltd right now?
Key figures of CollPlant Biotechnologies Ltd
How large is the market capitalisation of CollPlant Biotechnologies Ltd (CLGN)?
What is the P/S ratio of CollPlant Biotechnologies Ltd (CLGN)?
What are the earnings per share of CollPlant Biotechnologies Ltd (CLGN)?
What is the return on equity of CollPlant Biotechnologies Ltd (CLGN)?
What is the EBIT return on assets of CollPlant Biotechnologies Ltd (CLGN)?
What is the operating margin of CollPlant Biotechnologies Ltd (CLGN)?
How fast is revenue growing at CollPlant Biotechnologies Ltd (CLGN)?
How much free cash flow does CollPlant Biotechnologies Ltd (CLGN) generate?
How much net cash does CollPlant Biotechnologies Ltd (CLGN) hold?
Watch CollPlant Biotechnologies Ltd in the live analysis
One click puts CollPlant Biotechnologies Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.